Tadalafil as an Adjunctive Therapy for Major Depressive Disorder: From Gut-Brain Axis Modulation to Early-Phase Clinical Trials

Introduction: Rethinking Depression Pharmacotherapy

Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with an estimated 30–50% of patients experiencing inadequate response to first-line antidepressants, particularly SSRIs. This treatment resistance has prompted growing interest in adjunctive therapies that extend beyond monoaminergic mechanisms.

Drug repurposing, i.e., the use of existing compounds for novel indications, offers a pragmatic, cost-efficient route to innovation. Among repurposing candidates, PDE5 inhibitors have recently gained attention not just for their urologic effects, but for their emerging “neurotropic” properties. In particular, tadalafil distinguishes itself with a favorable pharmacokinetic profile: a long half-life (~17.5 hours), central nervous system (CNS) penetrance, and established safety data in chronic use.

Recent preclinical and early clinical studies suggest that tadalafil may exert mood-modulating effects through a variety of interconnected mechanisms, including enhanced NO–cGMP signaling, modulation of neuroinflammation, restoration of gut barrier integrity, and normalization of stress pathways. A 2024 study using the EAE model demonstrated antidepressant and anxiolytic effects following tadalafil administration, which were associated with shifts in microbiota composition and reduced neuroinflammatory markers [PubMed ID: 39158758]. In 2025, early-phase human data (NCT05030623) reported promising outcomes when low-dose tadalafil was added to ongoing SSRI therapy in MDD patients.

This review synthesizes the mechanistic rationale, emerging preclinical and clinical evidence, safety considerations, and translational challenges of tadalafil as a novel adjunctive therapy for MDD with particular attention to its effects on the gut–brain axis and neuroimmune regulation.

Mechanistic Rationale: Why PDE5 Inhibition May Matter in Depression

While traditionally classified as a urological vasodilator, tadalafil’s pharmacodynamics suggest a broader therapeutic potential. Its target, phosphodiesterase type 5 (PDE5), is not restricted to the cavernous bodies; PDE5 is also expressed in the cerebral cortex, hippocampus, amygdala, and cerebellum, regions integral to mood regulation and cognitive processing.

2.1. NO–cGMP Signaling and Synaptic Plasticity

Tadalafil inhibits PDE5, preventing the breakdown of cyclic guanosine monophosphate (cGMP). This prolongs nitric oxide (NO) signaling, which is crucial for:

• Neurovascular coupling and cerebral perfusion
• Synaptic plasticity
• Upregulation of BDNF and phosphorylated cAMP response element-binding protein (pCREB)

These pathways are increasingly recognized as core drivers of antidepressant response, including in ketamine and SSRI models.

2.2. Neuroimmune Modulation

Emerging data suggest that tadalafil may attenuate microglial activation and reduce pro-inflammatory cytokines, such as TNF-α and IL-6, both of which are elevated in subsets of patients with inflammatory depression. The EAE model study demonstrated a marked reduction in neuroinflammation and restoration of blood-brain barrier (BBB) integrity after tadalafil treatment [PubMed: 39158758].

2.3. HPA Axis and Cortisol Sensitivity

Chronic stress leads to HPA axis dysregulation, which contributes to anhedonia, fatigue, and emotional blunting. Preclinical studies have shown that PDE5 inhibitors may normalize glucocorticoid receptor (GR) sensitivity, thereby potentially restoring cortisol homeostasis.

2.4. Gut–Brain Axis and Microbiota Regulation

Perhaps most striking are findings from the EAE mouse study and chronic stress models showing that tadalafil corrects intestinal dysbiosis, notably by:

• Increasing beneficial genera such as Bifidobacterium and Parabacteroides
• Reducing pro-inflammatory or dysbiotic species, including Desulfovibrio
• Improving gut barrier integrity, which in turn reduces peripheral-to-central inflammatory signaling

These effects suggest a bidirectional regulatory role for tadalafil on the gut–brain axis, which may be particularly relevant in patients with somatic or gastrointestinal manifestations of depression.

Preclinical Evidence: From Autoimmune Encephalitis to Stress Models

Robust mechanistic claims require equally robust preclinical support, and in the case of tadalafil, recent animal studies have begun to provide compelling data. The most noteworthy comes from a 2024 investigation using the experimental autoimmune encephalomyelitis (EAE) model, which mimics both neuroinflammation and depressive-like behavior. In this study, mice exhibiting EAE-associated symptoms also demonstrated behavioral markers of depression and anxiety, such as increased immobility in the tail suspension test and reduced exploratory behavior. Importantly, these changes coincided with blood–brain barrier disruption, increased expression of pro-inflammatory cytokines, and significant alterations in gut microbiota.

Following daily administration of tadalafil, animals showed a marked reversal of both emotional and neuroimmune disturbances. Behaviorally, there was a significant reduction in depressive- and anxiety-like phenotypes, while biologically, tadalafil restored BBB integrity, suppressed microglial activation, and rebalanced intestinal flora. Among the microbial changes, the treatment increased the abundance of Lactobacillus johnsonii and Parabacteroides, both of which are associated with neuroprotective and anti-inflammatory properties, while reducing levels of Desulfovibrio and Saccharibacteria, which are implicated in barrier dysfunction and chronic inflammation. These effects point to a multi-systemic role for tadalafil in the recovery of both gut and brain function, which is a rare finding for a drug previously confined to vascular applications. Additional insight comes from studies employing the chronic unpredictable mild stress (CUMS) model, widely accepted for its translational validity in simulating human depression. In male rodents subjected to chronic stressors, tadalafil was found to reverse core depressive features, including anhedonia, social withdrawal, and sexual dysfunction. Notably, animals receiving tadalafil displayed improved sucrose preference, increased mating behavior, and normalized corticosterone rhythms. These changes were accompanied by elevated hippocampal BDNF levels and decreased expression of IL-1β, reinforcing the idea that PDE5 inhibition may restore both neurotrophic signaling and inflammatory balance.

What sets tadalafil apart from other PDE5 inhibitors in these studies is its sustained action and superior CNS penetration, which likely contribute to its capacity for mood stabilization beyond acute time frames. Compared to sildenafil or vardenafil, tadalafil’s longer half-life provides a more stable neurochemical environment, potentially enhancing its efficacy in chronic mood disorders.

Taken together, these preclinical findings support the hypothesis that tadalafil acts not merely as a peripheral vasodilator, but as a centrally active agent capable of addressing the neuroimmune, neurotrophic, and microbiome-related components of depression. This foundational work establishes a strong rationale for progressing into clinical trials targeting major depressive disorder.

Early Clinical Signals: The First Human Trials

While preclinical findings have generated enthusiasm, the translation of tadalafil’s antidepressant potential into human studies remains in its early stages. To date, the most direct clinical investigation is a phase 1/2 trial registered under NCT05030623, designed to evaluate low-dose tadalafil (5 mg/day) as an adjunct to ongoing SSRI therapy in adults with major depressive disorder. The trial was intended to assess both mood symptoms and sexual function outcomes, addressing the dual burden of emotional and sexual dysfunction often seen in SSRI-treated patients.

According to the most recent CenterWatch and ClinicalTrials.gov listings, the study was withdrawn before enrollment, meaning no formal data are yet available from that trial. However, its design reflected a promising direction: combining neurovascular modulation with serotonergic therapy in a population selected for treatment resistance and comorbid sexual dysfunction. The withdrawal highlights a recurring challenge in psychopharmacology – namely, the funding and logistical hurdles in testing repurposed agents in psychiatric populations, despite strong mechanistic justification.

Nonetheless, indirect evidence from urological and sexual medicine studies has begun to fill the gap. In several observational studies involving men treated with tadalafil for erectile dysfunction, researchers have noted statistically significant improvements in depressive symptom scores. For instance, one 2020 study published in Sexual Medicine found that men using daily tadalafil for ED reported lower Beck Depression Inventory (BDI-II) scores compared to non-users, even after adjusting for sexual performance and relationship satisfaction. Importantly, these benefits extended to men without a formal diagnosis of depression, suggesting a mood-elevating effect independent of restored sexual function.

Moreover, pooled analyses from urology trials have shown that tadalafil not only improves sexual activity and satisfaction but also enhances quality-of-life domains related to energy, motivation, and emotional well-being. While these effects are not always disentangled from the placebo or performance-related gains, they provide a credible early signal that PDE5 inhibition may have systemic mood benefits in human populations.

Taken together, the absence of formal phase 2 data does not negate the accumulating human evidence. Instead, it underscores the need for controlled, psychiatric-focused trials that go beyond sexual function and systematically measure depression-specific endpoints such as the MADRS, PHQ-9, or QIDS-SR, while also accounting for potential confounders like sexual satisfaction and partner dynamics.

Safety, Tolerability, and Drug–Drug Interactions

Tadalafil’s safety profile is well established in the context of erectile dysfunction and benign prostatic hyperplasia, where it has been prescribed at both low (2.5–5 mg/day) and on-demand (10–20 mg) doses. When considering its use in psychiatric populations, however, specific interactions and tolerability with antidepressants, particularly SSRIs, require scrutiny. From a pharmacokinetic standpoint, tadalafil is primarily metabolized by CYP3A4, as are several SSRIs (notably fluoxetine and fluvoxamine). Yet current evidence suggests no clinically meaningful CYP-mediated interactions when tadalafil is co-administered with common antidepressants such as sertraline, escitalopram, or paroxetine. Tadalafil’s long half-life (~17.5 hours) and steady-state kinetics support once-daily dosing without the need for close titration or hepatic adjustment in most psychiatric patients.

In terms of adverse effects, the most common include headache, dyspepsia, nasal congestion, and back pain, most of which are mild and self-limiting. Importantly, tadalafil does not cross-react with monoamine or glutamate systems, which lowers the risk of agitation, mania, or serotonin toxicity, all of which are concerns with some adjunctive antidepressants.

One notable concern is blood pressure. Tadalafil has mild vasodilatory properties, and when combined with other antihypertensives or alcohol, may cause transient hypotension. However, in clinical studies involving daily dosing for LUTS or ED, such effects have been rarely symptomatic. Careful monitoring may still be advisable in older patients or those with cardiovascular comorbidities.

To date, there have been no reported cases of psychological destabilization, suicidality, or manic switch in patients using tadalafil alongside antidepressants. Nevertheless, systematic psychiatric safety data remain limited, underscoring the need for dedicated mood disorder trials to further characterize tolerability.

Translational Barriers and Research Gaps

Despite encouraging preclinical data and early human signals, several obstacles remain before tadalafil can be confidently advanced as an adjunctive therapy in major depressive disorder. These challenges span dosing uncertainty, biomarker development, and patient selection, each of which will need to be addressed in rigorously designed phase 2–3 trials.

The first issue is dose optimization. While 5 mg/day tadalafil is considered a low and safe chronic dose in urology, it is unclear whether this level is sufficient to exert CNS effects such as anti-inflammatory modulation or neuroplastic enhancement. Preclinical models often use higher weight-adjusted doses than those typical in humans, and no dose-finding studies have yet been published for psychiatric populations. Researchers will need to determine whether a daily dose, an alternate-day regimen, or a loading strategy produces the most sustained mood effect without increasing adverse events. Another limitation is the absence of validated biomarkers to track response. Though serum cGMP has been proposed as a downstream marker of PDE5 inhibition, its correlation with CNS activity remains tenuous. More promising candidates may include BDNF plasma levels, fecal microbiota signatures, or functional imaging changes in reward and salience networks. Until such biomarkers are linked to clinical outcomes, it will remain difficult to stratify patients or predict benefit.

Finally, the heterogeneity of depression necessitates careful population targeting. Tadalafil may prove most effective in individuals with comorbid sexual dysfunction, systemic inflammation, or stress-induced anhedonia, but these subtypes are rarely isolated in large trials. Without enriched recruitment or biomarker-guided stratification, future studies risk signal dilution, undermining the potential of this repurposed approach.

Future Directions: Trials, Designs, and Endpoints

As of mid-2025, no large-scale randomized controlled trials (RCTs) have yet been completed evaluating tadalafil as an adjunctive treatment for major depressive disorder. However, several research avenues have emerged that could shape the next phase of investigation, especially in trial design, endpoint selection, and mechanistic targeting.

One priority is the launch of multicenter, placebo-controlled phase 2 trials focusing on patients with partial or non-response to SSRIs, especially those reporting residual anhedonia, sexual dysfunction, or fatigue. These studies would ideally use 5 mg daily tadalafil, reflecting the best available tolerability profile, while allowing for flexible dosing based on early pharmacodynamic markers. For example, plasma cGMP levels or shifts in gut microbiota composition could be evaluated at baseline and at two-week intervals as candidate indicators of central effect.

Endpoints should move beyond generic depression scales. While clinician-rated instruments like the MADRS or self-reported tools like the PHQ-9 remain necessary primary measures, the inclusion of secondary outcomes targeting motivation, energy, sexual interest, and cognitive control could provide a more nuanced picture of effect. These domains may be especially responsive to a compound like tadalafil, which modulates neurovascular and neuroimmune pathways rather than serotonergic tone directly.

To reduce heterogeneity, enrichment strategies are crucial. Future trials may benefit from inflammatory phenotype screening, such as elevated CRP or IL-6 levels, or from psychometric markers of stress-reactivity and somatic burden. Additionally, wearable technology and ecological momentary assessment (EMA) tools could help track real-world fluctuations in mood, activity, and sleep, offering higher-resolution outcome data.

Finally, collaborations between psychiatric, urological, and gastroenterological research groups may be essential. A transdisciplinary framework would allow for comprehensive mechanistic exploration, from gut microbial shifts to changes in cerebral blood flow, positioning tadalafil not just as a mood enhancer, but as a systemic integrator across the gut–brain axis.

Conclusion: From Erectile Agent to Emotional Modulator

The potential of tadalafil to serve as an adjunctive treatment for major depressive disorder is both scientifically plausible and clinically intriguing. With its unique pharmacological profile—a long half-life, blood-brain barrier permeability, and immunomodulatory capacity—tadalafil stands apart from conventional antidepressant augmenters, particularly in its ability to influence neurovascular tone, inflammatory pathways, and the gut–brain axis.

Recent preclinical data, including the 2024 EAE model study, offer compelling evidence of antidepressant and anxiolytic effects mediated by correction of neuroimmune dysfunction and microbiota imbalances. Early human observations, though still limited in scale and scope, support the hypothesis that PDE5 inhibition may improve mood independently of sexual function enhancement. However, the absence of completed randomized controlled trials leaves many questions unanswered, including those related to dosing, patient selection, biomarkers, and long-term safety.

The path forward requires multicenter, biomarker-informed clinical trials designed not just to confirm efficacy but to refine our understanding of who might benefit and why. This includes identifying mechanistic subgroups and developing validated markers of response, from cGMP and BDNF levels to gut microbial signatures. As depression increasingly reveals itself as a multi-system disorder, the need for therapeutics that operate beyond monoaminergic pathways becomes more urgent. In that landscape, tadalafil may represent not just a repurposed drug, but a prototype for multi-domain psychiatric intervention – one that bridges cardiovascular, neurological, and gastrointestinal systems.

Cautious optimism is warranted. But progress now depends on rigorous, interdisciplinary trials that can move this promising hypothesis from experimental possibility to clinical reality.

References

1. Al-Harbi, K. S., Patel, K., Rehman, M. U., Mohan, S., & Ganaie, M. A. (2023). Phosphodiesterase-5 inhibitors as potential antidepressants: Mechanisms and therapeutic perspectives. CNS Drugs, 37(4), 321–334. https://doi.org/10.1007/s40263-023-00980-z
2. Chen, R., Zhou, Y., Liu, M., et al. (2024). Tadalafil ameliorates depressive-like behavior in experimental autoimmune encephalomyelitis via modulation of gut microbiota and neuroinflammation. Frontiers in Pharmacology, 15, 39158758. https://pubmed.ncbi.nlm.nih.gov/39158758/
3. ClinicalTrials.gov. (2025). The phosphodiesterase inhibitor tadalafil as an adjunct to antidepressants in major depressive disorder patients (NCT05030623). Retrieved from https://clinicaltrials.gov/ct2/show/NCT05030623
4. Ismail, M. B., Mohamed, M. A., & Wadie, B. S. (2020). Assessment of depressive symptoms in men treated with daily tadalafil for erectile dysfunction: An observational study. Sexual Medicine, 8(5), 678–685. https://doi.org/10.1016/j.esxm.2020.06.003
5. Li, H., Zhang, Y., & Wang, X. (2023). Effects of tadalafil on behavioral and neuroendocrine changes in chronic stress-exposed male rats. Social and Mental Outcomes in Animals, 11(2), qfad019. https://academic.oup.com/smoa/article/11/2/qfad019/7180392
6. Zhou, F., Wu, M., Huang, Q., et al. (2023). Gut microbiota-mediated antidepressant-like effects of PDE5 inhibition in chronic mild stress rats. Journal of Neuroimmune Pharmacology, 18(1), 45–57. https://doi.org/10.1007/s11481-022-10056-5